Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. CytoDyn Inc (CYDY) Message Board

Is phase 3 data not even enough?? As mentioned, t

Message Board Public Reply | Private Reply | Keep | Replies (4)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 153887
(Total Views: 657)
Posted On: 10/26/2020 2:47:47 PM
Posted By: Lee Ron Lemab
Re: viridi #63239
Is phase 3 data not even enough?? As mentioned, the world is in crisis and the SOC for this pandemic is remdesivir (which is basically placebo+ assult on your liver, already perhaps being assulted by the cytokine storm) and dexamethasone (which is great for reducing inflammation and no doubt saving some lives).

When millions of people are dying around the world, treatments that work/save lives must be expiteded - especially treatments that have proven to have a better safety profile than SOC and have an MOA that reduces viral load and calms the cytokine storm that ravages organs.

This drug is tested in over 1000 people proving safety (no side effects) and phase 3 of CD12 would prove more efficacy in addition to CD10 data. Is that really not enough for an EUA? Remdesivir got an EUA and it is bad for the liver, an organ with over 300+ important metabolic functions. With that, it became the SOC and got full approval. It's not proven to be any better than placebo in saving lives and even apsirin is proving to save lives for covid patients - https://www.sciencedaily.com/releases/2020/10...195637.htm .

Saving lives is what this world needs and if phase 3 proves Leronlimab saves lives for covid patients than why the need for phase 4?

If CD12 data proves efficacy at next interim analysis (on mortality, one of the hardest primary endpoint to achieve), why would more testing be needed? Especially if people are dying by the 100s of thousands with current SOC.

Starting to feel like I'm being given a path of small bread crumbs with stories of a great meal at the end of them, provided I find and eat each one.

I can already imagine a CC at the end of the next interim analysis or even in completion of a successful phase 3 "We got the best news we could have possibly received (other than getting EUA), and we excited to do a phase 4 with 700 patients. We know we will get them quicker now that the remdesivir trials are over and look fowrard to providing the FDA what they want for the EUA."

I understand in normal times trials are 4 full phases, but this is more than a rush to improve SOC and safe countless lives for an out of control pandemic!!

If this system is THIS dysfunctional I'd like to know. It's getting worse the more I learn. Please reply if you have insights about the need for a phase 4 if phase 3 shows safety and efficacy (including hitting stastical sign. on primary endpoint - mortality.

Thanks


(2)
(1)




CytoDyn Inc (CYDY) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us